Open AccessClinical end pharmacoeconomic aspects of neoadjuvant therapy of breast cancer
Author(s) -
V. Kostorov,
Т. Ю. Семиглазова,
А. В. Павлыш
Publication year - 2018
Publication title -
medicinskij sovet
Language(s) - English
Resource type - Journals
eISSN - 2658-5790
pISSN - 2079-701X
DOI - 10.21518/2079-701x-2018-10-140-145
Subject(s) - breast cancer , medicine , neoadjuvant therapy , oncology , cancer , blockade , receptor
Achievement of complete Pathomorphologic Response (pCR) after neoadjuvant therapy of breast cancer significantly improves long-term treatment outcome. Correlation between pCR and long-term treatment outcome is strongest in HER2-positive breast cancer; this data clearly supports use of double HER2-blockade in neoadjuvant breast cancer therapy. However, the high cost of targeted drugs requires pharmacoecomomic assessments for choosing of the most optimal treatment course.